Under the agreement, PharmAbcine will use Thermo Fisher's Quick to Clinic integrated service offering, a program that accelerates drug development for investigational new drug (IND) submissions for phase I clinical trials.

PMC-309 is a fully human monoclonal antibody (immunoglobulin G) that targets the epitope of human V-domain immunoglobulin suppressor of T-cell activation (VISTA) that is primarily expressed on myeloid-derived suppressor cells. Inhibition of VISTA-positive immunosuppression is a promising immunotherapeutic strategy and an alternative to PD1/PDL1 targeting immuno-oncology drugs.

The drug will be developed at Thermo Fisher's site in Princeton, NJ, and PharmAbcine plans to initiate IND-enabling studies this year and submit global IND in 2021.

Sloan Kettering, Hackensack form immunology collaboration
Memorial Sloan Kettering and Hackensack Meridian Health have formed an immunology research collaboration to support cancer immunotherapy research.

Thermo Fisher to operate new CSL biologics facility
Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.

Thermo releases spectrometry products for proteomics
Thermo Fisher Scientific has announced an exclusive license agreement with software firm MSAID for intelligent software that uses deep learning facilitated...

Thermo Fisher to double viral vector manufacturing capacity
Thermo Fisher Scientific is expanding its viral vector development and manufacturing services with construction of a new commercial manufacturing site...

AGC Biologics, Faron to manufacture cancer immunotherapy
Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.